Erin Stansbury
Family · Sioux Falls, SDNPI 1407337819
Payments from drug & device makers
Across 102 payments — averaging $16.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Dexcom, Inc.$498
- Medtronic$324
- Insulet Corporation$212
- Boehringer Ingelheim$147
- Sanofi-aventis U.S. LLC$85
- Kyowa Kirin, Inc.$64
- plus $387 from 13 others
What the payments were for
- Food & beverage$1,718100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Dexcom, Inc. | 41 | $498 |
| Medtronic | 14 | $324 |
| Insulet Corporation | 11 | $212 |
| Boehringer Ingelheim | 9 | $147 |
| Sanofi-aventis U.S. LLC | 4 | $85 |
| Kyowa Kirin, Inc. | 3 | $64 |
| Abbott | 3 | $53 |
| Xeris Pharmaceuticals, Inc. | 2 | $46 |
| Novo Nordisk | 2 | $44 |
| Tandem Diabetes Care, Inc. | 2 | $38 |
| Zealand Pharma US, Inc. | 2 | $37 |
| BD | 1 | $31 |
| AstraZeneca | 2 | $25 |
| Amryt Pharma Holdings Ltd | 1 | $22 |
| Ultragenyx Pharmaceutical Inc. | 1 | $20 |
| Amphastar Pharmaceuticals, Inc. | 1 | $20 |
| Corcept Therapeutics | 1 | $18 |
| Bayer | 1 | $17 |
| Sequel Med Tech, LLC | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MINIMED 780G$133
How this compares
$1,718 in reported general payments places this provider in the 85th percentile of 588 family providers in South Dakota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 402 | $548,699 |
| OzempicSemaglutide | 341 | $459,687 |
| JardianceEmpagliflozin | 166 | $201,075 |
| Tresiba Flextouch U-200Insulin Degludec | 130 | $122,604 |
| TrulicityDulaglutide | 55 | $73,827 |
| Humalog Kwikpen U-200Insulin Lispro | 51 | $60,675 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 45 | $54,216 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 46 | $51,272 |
| FarxigaDapagliflozin Propanediol | 65 | $50,607 |
| Tresiba Flextouch U-100Insulin Degludec | 80 | $48,312 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 16 | $43,099 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 94 | $37,271 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 40 | $36,201 |
| Novolog FlexpenInsulin Aspart | 123 | $34,885 |
| Lyumjev Kwikpen U-200Insulin Lispro-Aabc | 12 | $30,445 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog, Tresiba | $44 | $505,788430 claims |
| Boehringer IngelheimJardiance, Tradjenta | $147 | $214,516183 claims |
| AstraZenecaFarxiga | $25 | $50,60765 claims |
| Sanofi-aventis U.S. LLCLantus | $85 | $2,98839 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 588 family providers in South Dakota.
Other family in Sioux Falls
- Brittany WangsnessSioux Falls$79K
- Stephanie PreisterSioux Falls$12K
- Michelle VanhoveSioux Falls$7K
- Heidi FurthSioux Falls$6K
- Tabitha AmmannSioux Falls$6K
- Megan MoedingSioux Falls$5K
- Kari WestenkirchnerSioux Falls$4K
- Brooke MunkSioux Falls$4K
- Rebekka KlemmeSioux Falls$4K
- Jordyn HoferSioux Falls$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.